Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800545 | 0.90 | KDM4E (0.47) | RAF1MAP2K1KDM4EALDH1A1SSTR4 | |
| SCHEMBL1797654 | 0.87 | LPAR1 (0.43) | — | |
| SCHEMBL1800515 | 0.83 | CYP2D6 (0.47) | RAF1MAP2K1KDM4EALDH1A1SSTR4 | |
| SCHEMBL1797314 | 0.80 | SSTR4 (0.43) | RAF1MAP2K1KDM4EALDH1A1SSTR4 | |
| SCHEMBL1798511 | 0.78 | MLNR (0.43) | KDM4E | |
| SCHEMBL7864555 | 0.77 | KDM4E (0.45) | RAF1MAP2K1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL22746859 | 0.77 | SSTR4 (0.56) | KDM4EALDH1A1SSTR4CYP1A2TDP1 | |
| SCHEMBL1800492 | 0.77 | RAF1 (0.45) | RAF1MAP2K1KDM4EALDH1A1SSTR4 | |
| SCHEMBL6018304 | 0.76 | LPAR1 (0.44) | RAF1MAP2K1KDM4EALDH1A1POLB | |
| SCHEMBL30441397 | 0.76 | RAF1 (0.49) | RAF1MAP2K1KDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-1996566-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106016-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | RAF1 2030/4885MAP2K1 3563/4885HCRTR1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.